CARDIALYSIS And Sticares InterACT Announce Strategic Collaboration

| Print |
Thursday, 23 September 2010 16:30 (UTC + 2)
Cardialysis_logo sticares_logo

 

Rotterdam and Rhoon, The Netherlands, September 23, 2010 / b3c newswire /Cardialysis and Sticares InterACT, both Contract Research Organizations (CROs) headquartered in The Netherlands, announced today that they have entered into a strategic collaboration to provide drug development consulting services in the field of cardiovascular and metabolic medicine. Both organizations have substantial experience and success in the execution of clinical research projects for pharmaceutical, biotechnology and medical device companies. 

 

Cardialysis and Sticares InterACT have been independently active for more than 25 years conducting high-quality cardiovascular and metabolic focused clinical research.  Each of the two companies has unique and complementary service offerings and both share a common history with roots planted firmly in academia. Strong ties to cardiologists, physicians, research scientists, and key opinion leaders allow for easy access to leading drug development knowledge. As a result of their academic origins, Sticares InterACT and Cardialysis are able to offer expert drug development services well beyond that of ordinary CROs.

 

“The synergy resulting from this collaboration offers sponsors concrete and exceptional advantages”, states Karen Keukelaar, COO of Sticares InterACT.  “Cardialysis has its strengths in core laboratory techniques and web-based clinical event adjudication, statistics, data management and clinical trial management whereas Sticares InterACT excels in clinical project management, site management in 26 countries with a strong presence in Eastern Europe, medical monitoring, event management and pharmacovigilance. So, we are very complementary”.

 

Driek Vergouwen, CEO of Cardialysis, adds: “Joining strengths means that our organizations together can offer complete clinical research services to our customers that combine scientific know-how with broad medical experience and outstanding international execution. Our mutual specialization in cardiology and metabolic diseases for many years makes us the preferred international partner for companies in need of high quality clinical studies in these fields.”

 

The collaboration between Cardialysis and Sticares InterACT ensures high quality clinical research services, accelerated subject recruitment, therapeutic competence and medical expertise for current and future clients. Cardialysis and Sticares InterACT together offer a complete spectrum of services from pre-clinical consulting to planning, managing, executing and reporting  phase II-IV clinical research programs.

 

 

About Cardialysis - www.cardialysis.com
Cardialysis is an independent clinical CRO offering high quality services in the field of cardiology with focus on interventional cardiology and electrophysiology with both medical devices and pharmacological treatments. Cardialysis is recognised for its opinion-leader expertise, strong academic network, statistical expertise, innovative core laboratory technologies and imaging techniques, event adjudication and professional execution of clinical trials. Cardialysis has been facilitating clinical trials for medical devices and pharmaceutical products since 1984 and has gained ample experience in phase II, phase III and CE-mark clinical trials. Cardialysis has successfully executed many landmark trials, amongst which BENESTENT, RAVEL, ARTS 1 and 2 and ABSORB.

 

About Sticares InterACT - www.sticaresinteract.com
Sticares InterACT is the contract research arm of the Sticares Cardiovascular Research Institute, an independent institute established in 1981 in the Netherlands. Sticares InterACT provides an extensive range of services including clinical project management, site management, medical monitoring, event management and pharmacovigilance to pharmaceutical, biotechnology and medical device companies. Sticares InterACT is currently present in 26 European countries with access to a broad network of investigators guaranteeing high patient recruitment rates, whilst world-wide coverage is provided by its GlobalACT partnership.
In addition, Sticares InterACT offers outstanding consultancy services through its Scientific Advisory Board and the Sticares Cardiovascular Research Institute. Sticares InterACT has been involved in many phase II-IV clinical trials in angina, acute coronary syndrome, secondary prevention of CAD, heart failure, hypertension, diabetes, hyperlipidemia and atherosclerosis and has successfully managed multinational landmark studies including EUROPA, HYVET, PREAMI, BEAUTIFUL and SHIFT.


Contact
CARDIALYSIS BV
Mark Neijssel
PO Box 2125, 3000 CC Rotterdam
Westblaak 92, 3012 KM Rotterdam
The Netherlands
Tel.: +31 (0)10 206 2828
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.cardialysis.com